Table 5.
Protective effects of the rIFNα-2b nasal spray against viral respiratory infections (intention-to-treat analysis).
| Viruses | EER (%) | CER (%) | RR (95% CI) | ARR (%) (95% CI) | RRR (95% CI) | NNT (95% CI) |
|---|---|---|---|---|---|---|
| ADV | 3.0 | 7.1 | 0.405 (0.165–0.994) | 4.1 (0.2–8.0) | 0.595 (0.006–0.835) | 25 (12.5–553.9) |
| RSV | 0.8 | 2.7 | 0.279 (0.057–1.356) | 2.0 (−0.3 to 4.2) | 0.721 (−0.356 to 0.943) | 51 (−319.3 to 23.6) |
| Flu-A | 6.4 | 22.6 | 0.232 (0.151–0.357) | 16.3 (11.8–20.7) | 0.768 (0.643–0.849) | 7 (4.8–8.4) |
| Flu-B | 4.2 | 16.2 | 0.230 (0.141–0.374) | 12.6 (8.9–16.3) | 0.770 (0.626–0.859) | 8 (6.1–11.3) |
| PIV1-3 | 4.0 | 15.8 | 0.225 (0.139–0.365) | 11.8 (8.3–15.2) | 0.775 (0.635–0.861) | 9 (6.6–12.1) |
EER: experimental event rate; CER: control event rate; RR: relative risk; ARR: absolute risk reduction; RRR: relative risk reduction (equal to protective rate); NNT: number needed to treat.